---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-24-005064"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2024-04-09T23:59:59+00:00"
generated_at: "2026-06-04T01:01:09.624552+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "low"
source: SEC EDGAR
---

# ADC Therapeutics presents exatecan-based ADC platform at virtual investor event

## Summary
- CEO Ameet Mallik and CSO Patrick van Berkel to present updates on novel exatecan-based ADC platform.
- Agenda includes business update, research strategy, platform, and lead candidates.
- Presentation made available on April 9, 2024, with live Q&A session to follow.
- No financial results or material non-public information disclosed in the filing.

## SEC filing metadata
- accession: 0000950103-24-005064
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2024-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000095010324005064/0000950103-24-005064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000095010324005064/dp209553_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-24-005064
- JSON: https://secwatch.observer/filing/0000950103-24-005064.json
- Plain text: https://secwatch.observer/filing/0000950103-24-005064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.